all press releases

  • 03/22/16
    IRVING, Texas--(BUSINESS WIRE)--Technology advances for coronary, peripheral and neuro vascular devices continue to drive changes to the market and non-clinical hospital staff must stay informed. To meet the needs of non-clinical staff, Vizient, Inc. has published a new edition of its Technology Watch. “The cardiovascular, peripheral vascular and neuro endovascular market is dynamic with revolutionary devices securing FDA approval. Adding to the dynamics is the changingmore...
  • 03/07/16
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc., the largest member-owned health care company in the country, has been recognized by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices, as a 2016 World’s Most Ethical Company®. This year marks the tenth anniversary of Ethisphere and the World’s Most Ethical Company designation, which recognizes those companies who align principle with action, workmore...
  • 03/03/16
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. today announced that Mark Cartwright, senior director of Supplier Diversity has been recognized for his leadership and service as a supplier diversity professional by Women’s Enterprise USA Magazine (WE USA) and the US Pan Asian American Chamber of Commerce (USPAACC) Southwest Region. Vizient, Inc., the largest member-owned health care company in the country, is dedicated to serving members and customers throughmore...
  • 02/29/16
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. today announced that its expanded relationship with UConn Health has achieved significant savings, realizing more than 100% of the 18-month committed savings target, after only six months into the agreement. UConn Health began utilizing supply chain and cost analytics software solutions, augmenting their medical/surgical and other commodity group purchasing relationship with MedAssets, beginning in July 2015more...
  • 02/19/16
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. today announced it has presented on the role of U.S. group purchasing organizations in the radiopharmaceutical supply chain at the Organisation for Economic Co-operation and Development (OECD) Nuclear Energy Agency’s (NEA) 1st Meeting of the 4th Mandate of the High-level Group on the Security of Supply of Medical Radioisotopes (HLG-MR). The NEA established the HLG-MR in 2009 to examine the underlyingmore...
  • 02/18/16
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. today announced it has been named to the annual "America's Top 50 Organizations for Multicultural Business" list by DiversityBusiness.com. This elite list, also known as the “Div50”, recognizes companies for providing business opportunities to diverse business owners throughout the United States. Over 1,500,000 businesses were surveyed by DiversityBusiness.com, the nation’s leading multicultural B2B online websitemore...
  • 02/15/16
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. (“Vizient”) today announces it has completed the acquisition of MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, from Pamplona Capital Management. The combined organization represents the nation’s top hospitals and health systems, and they have delivered billions in savings to providers over the past two years alone. By joining the organizations’ proven strengths in group purchasing,more...
  • 02/05/16
    IRVING, Texas--(BUSINESS WIRE)--Citing the escalating costs for certain commonly used biologics and the associated expenses for its members of over $6 billion, Vizient, Inc. has sent a letter to the Food and Drug Administration’s (FDA) Arthritis Advisory Committee endorsing the continued implementation of the U.S. biosimilar pathway. On February 9, 2016, the committee is scheduled to hold an advisory hearing on an application for a biosimilar version of infliximab,more...
  • 01/14/16
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. (“Vizient”) today announces the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connection with the acquisition of MedAssets’ (NASDAQ: MDAS) Spend and Clinical Resource Management (SCM) segment, including Sg2, from Pamplona Capital Management (“Pamplona”). The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisitionmore...
  • 01/14/16
    MedAssets, Inc. today announced that its stockholders approved the previously disclosed Agreement and Plan of Merger ("Merger Agreement") with Pamplona Capital Management LLP at its special meeting of stockholders held today.Based on the tabulation of the stockholder vote, approximately 99.8% of the total votes cast, which represented approximately 89.7% of the total shares outstanding as of the November 24, 2015 record date for the special meeting, were voted in favor of the approval andmore...

Connect with us